Pflugfelder Stephen C
Baylor College of Medicine, 6565 Fannin, NC-205, Houston, TX 77030, USA.
Am J Manag Care. 2008 Apr;14(3 Suppl):S102-6.
Data from a large US managed care database suggest that the prevalence of clinically diagnosed dry eye disease (DED) is 0.4% to 0.5% overall, and is highest among women and the elderly. The burden of DED to the patient can be substantial, impacting visual function, daily activities, social and physical functioning, workplace productivity, and quality of life (QOL). Preliminary analysis suggests that DED also has a considerable economic impact in terms of both direct and indirect costs. A number of therapies have been shown to improve DED signs and symptoms, but few clinical trials have addressed QOL and economic issues. Limited data suggest that topical cyclosporine has the potential to reduce physician visits and use of other medications, including artificial tears; however, further research is needed to clarify its impact on both the direct and indirect costs of DED.
来自美国一个大型管理式医疗数据库的数据表明，临床诊断的干眼症（DED）总体患病率为0.4%至0.5%，在女性和老年人中患病率最高。干眼症给患者带来的负担可能很大，会影响视觉功能、日常活动、社交和身体功能、工作场所生产力以及生活质量（QOL）。初步分析表明，干眼症在直接和间接成本方面也具有相当大的经济影响。已证明多种疗法可改善干眼症的体征和症状，但很少有临床试验涉及生活质量和经济问题。有限的数据表明，局部用环孢素有可能减少就诊次数以及其他药物（包括人工泪液）的使用；然而，需要进一步研究以阐明其对干眼症直接和间接成本的影响。
